To explore the effect of early whole course immune nutrition supplementation in patients with previously untreated advanced pancreatic cancer:a prospective, single-arm, single-center clinical study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400091619

Enrollment

Unknown

Registered

2024-10-31

Start date

2024-11-01

Completion date

Unknown

Last updated

2024-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer

Interventions

Test group:1. Clinical anti-tumor treatment plan: According to the Chinese Guidelines for Diagnosis and Treatment of Pancreatic Cancer (2021 edition), oncologists will develop and implement standard a

500ml was taken orally daily (8.5g arginine, 0.9g nucleotide, and 2g omega-3 unsaturated fatty acids). The patient was given oral nutrition supplements (ONS) at 500ml/ day 1 to 3 days before the first

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically confirmed advanced pancreatic cancer (advanced pancreatic cancer is defined as local and/or distant metastases that cannot be surgically removed) 2. Not received systematic antitumor therapy before 3, Age 18-80 years old, gender unlimited 4. Eastern Cooperative Oncology (ECOG) has a baseline performance status of 0, 1, or 2 5. Life expectancy is more than 3 months 6. Clear mind, no communication barriers, can answer questions 7. Informed consent has been signed 8. Able to follow research protocols and follow-up procedures

Exclusion criteria

Exclusion criteria: 1. Allergies to certain nutrients 2. Participate in other clinical trials 3. Participants considered unsuitable for this experiment by the researchers 4. Subjects have concurrent or previous history of other tumors 5. Patients with peritoneal metastasis or ascites caused by tumor 6. Patients with infectious diseases, liver, kidney and other organ functions with serious abnormalities

Design outcomes

Primary

Measure	Time frame
Skeletal muscle index;	—

Secondary

Measure	Time frame
Patient quality of life score;Psychological score;Nutritional status;Cardiac function assessment;Peripheral blood biomarkers;1 year PFS rate;1 year OS rate;Safety;	—

Countries

China

Contacts

Public ContactDu Juan

The Affiliated Drum Tower Hospital to Medical School of Nanjing University

dujuanglyy@163.com+86 25 8310 6666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026